Mesenchymal stem cells for the adjunctive treatment of cytomegalovirus pneumonia in hematopoietic stem cell transplant recipients: a Single-center prospective study
Prospective study shows mesenchymal stem cells enhance overall survival in patients with CMV pneumonia, suggesting potential benefits as adjuvant therapy.
Key Points
The MSC treatment group showed a significant increase in overall survival at 74%, as compared to 50% in the non-MSC group.
While the cure rates differed (79% MSC vs. 63% non-MSC), the difference was not statistically significant, indicating further investigation is needed.
This prospective study monitored 43 patients over six years post-allo-HSCT, emphasizing the urgent need for more research on MSC effectiveness.
Despite improved overall survival, the time to cure did not show a significant difference, pointing to complexities in treatment outcomes.